JVS 100

Drug Profile

JVS 100

Alternative Names: ACRX-100; JVS-100; SRX-100

Latest Information Update: 09 Feb 2016

Price : $50

At a glance

  • Originator Cleveland Clinic
  • Developer Juventas Therapeutics; SironRX Therapeutics
  • Class Gene therapies; Heart failure therapies
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; CXCR4 receptor agonists; Gene transference; Leukocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Heart failure; Peripheral arterial disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure; Peripheral arterial disorders; Peripheral ischaemia
  • Phase I Scars
  • Preclinical Angina pectoris; Myocardial infarction

Most Recent Events

  • 04 Feb 2016 JVS 100 receives Fast Track designation for treatment of Ulcers in peripheral arterial disorders [IM,Injection] in USA
  • 01 Nov 2015 Phase-II clinical trials in Peripheral arterial disorders in USA (IM)
  • 04 Sep 2015 Juventas plans a phase II STOP-PAD trial for Peripheral arterial disorders in USA (NCT02544204)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top